Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A national network of medical technology incubators provides experiential training for the next generation of medical entrepreneurs and enables creation of innovative technologies for pressing clinical needs.
The agency’s ‘no-go’ for BioMarin’s hemophilia A gene therapy came as a surprise, but reflects outstanding questions as to the durability of the treatment.
Voluntary pledges to make intellectual property broadly available to address urgent public health crises can overcome administrative and legal hurdles faced by more elaborate legal arrangements such as patent pools and achieve greater acceptance than governmental compulsory licensing.
Several startups are now pursuing the potential of enzymatic synthesis as a faster and more efficient route for synthesizing longer DNA sequences than is possible with traditional chemical means.
Plasma from individuals who have recovered from COVID-19 could benefit sick patients, but definitive evidence for or against convalescent plasma is still lacking. A consensus about how it should be deployed is beginning to emerge—and tools and insights to guide its use are becoming available.
The scientific integrity of US government agencies is under attack from the Trump administration. Agency senior executives and industry leaders need to continue pushing back.
Can traditional computational analysis and machine learning help compensate for inadequate peer review of drug-repurposing papers in the context of an infodemic?